Download PDF
Hamostaseologie 2018; 38(02): 87-97
DOI: 10.1055/s-0038-1641586
Review Article
Schattauer GmbH Stuttgart

Diagnosis and Treatment of Pulmonary Embolism in Challenging Populations

Sebastian Werth
1   Center for Vascular Diseases, Division of Angiology, Department of Medicine III, University Hospital “Carl Gustav Carus” Dresden, Dresden, Germany
,
Jan Beyer-Westendorf
2   Thrombosis Research Unit, Division of Haematology, Department of Medicine I, University Hospital “Carl Gustav Carus” Dresden, Dresden, Germany
3   Kings Thrombosis Service, Department of Haematology, Kings College London, London, United Kingdom
› Author Affiliations
Further Information

Publication History

01 August 2017

17 January 2018

Publication Date:
29 May 2018 (online)

Also available at
   Permissions and Reprints

Abstract

Although the diagnostic and therapeutic approach to pulmonary embolism (PE) has been considerably improved and standardized in recent years, special populations such as pregnant patients and those with impaired renal function or cancer still represent a clinical challenge and a detailed knowledge about the available diagnostic and therapeutic alternatives is mandatory to provide best evidence-based care for these difficult-to-treat patients. Although this review aimed to summarize the most important aspects in this field, the reader is referred to the original studies cited here and dedicated guideline and guidance documents for more detailed information.

Zusammenfassung

Obwohl in den letzten Jahren Diagnostik und Therapie der Lungenembolie deutlich verbessert und standardisiert wurden, stellen Patienten in der Schwangerschaft, mit eingeschränkter Nierenfunktion oder einer Krebserkrankung immer noch eine klinische Herausforderung dar, und ein detailliertes Wissen um verfügbare diagnostische und therapeutische Alternativen ist Voraussetzung, um eine gute evidenz-basierte Versorgung dieser schwer zu behandelnden Patienten zu gewährleisten. Wenngleich diese Übersichtsarbeit die wichtigsten Aspekte hierzu zusammenzufasst, wird der Leser für weitergehende Informationen auf Originalarbeiten sowie Leitlinien zu diesem Thema verwiesen.

Keywords

pulmonary embolism - pregnancy - cancer - chronic kidney disease

Schlüsselwörter

Lungenembolie - Schwangerschaft - Krebserkrankung - chronische Nierenerkrankung
 

  • References

  • 1 Kearon C, Akl EA, Ornelas J. , et al. Antithrombotic therapy for VTE disease: Chest guideline and expert panel report. Chest 2016; 149 (02) 315-352
    CrossrefPubMedGoogle Scholar
  • 2 Konstantinides SV, Torbicki A, Agnelli G. , et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014; 35 (43) 3033-3069 , 3069a–3069k
    CrossrefPubMedGoogle Scholar
  • 3 Sullivan EA, Ford JB, Chambers G, Slaytor EK. Maternal mortality in Australia, 1973-1996. Aust N Z J Obstet Gynaecol 2004; 44 (05) 452-457 , discussion 377
    CrossrefPubMedGoogle Scholar
  • 4 CEMACH. CEMACH Saving Mothers' Lives: Reviewing maternal deaths to make motherhood safer - 2003–2005. The Seventh Report of the Confidential Enquiries into Maternal Deaths in the United Kingdom London: Centre for Maternal and Child Enquiries; 2008. Available at: http://www.publichealth.hscni.net/sites/default/files/Saving%20Mothers%27%20Lives%202003-05%20.pdf accessed on Nov 7; 2017
    PubMedGoogle Scholar
  • 5 Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton III LJ. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 2005; 143 (10) 697-706
    CrossrefPubMedGoogle Scholar
  • 6 Wells PS, Anderson DR, Rodger M. , et al. Excluding pulmonary embolism at the bedside without diagnostic imaging: management of patients with suspected pulmonary embolism presenting to the emergency department by using a simple clinical model and D-dimer. Ann Intern Med 2001; 135 (02) 98-107
    CrossrefPubMedGoogle Scholar
  • 7 Wells PS, Anderson DR, Rodger M. , et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med 2003; 349 (13) 1227-1235
    CrossrefPubMedGoogle Scholar
  • 8 Le Gal G, Righini M, Roy PM. , et al. Prediction of pulmonary embolism in the emergency department: the revised Geneva score. Ann Intern Med 2006; 144 (03) 165-171
    CrossrefPubMedGoogle Scholar
  • 9 Chabloz P, Reber G, Boehlen F, Hohlfeld P, de Moerloose P. TAFI antigen and D-dimer levels during normal pregnancy and at delivery. Br J Haematol 2001; 115 (01) 150-152
    CrossrefPubMedGoogle Scholar
  • 10 Chan WS, Chunilal S, Lee A, Crowther M, Rodger M, Ginsberg JS. A red blood cell agglutination D-dimer test to exclude deep venous thrombosis in pregnancy. Ann Intern Med 2007; 147 (03) 165-170
    CrossrefPubMedGoogle Scholar
  • 11 Chan WS, Lee A, Spencer FA. , et al. D-dimer testing in pregnant patients: towards determining the next ‘level’ in the diagnosis of deep vein thrombosis. J Thromb Haemost 2010; 8 (05) 1004-1011
    CrossrefPubMedGoogle Scholar
  • 12 Bates SM, Jaeschke R, Stevens SM. , et al. Diagnosis of DVT: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): e351S-e418S
    CrossrefPubMedGoogle Scholar
  • 13 Linnemann B, Bauersachs R, Rott H. , et al; Working Group in Women's Health of the Society of Thrombosis and Haemostasis. Diagnosis of pregnancy-associated venous thromboembolism - position paper of the Working Group in Women's Health of the Society of Thrombosis and Haemostasis (GTH). Vasa 2016; 45 (02) 87-101
    CrossrefPubMedGoogle Scholar
  • 14 Einstein AJ, Henzlova MJ, Rajagopalan S. Estimating risk of cancer associated with radiation exposure from 64-slice computed tomography coronary angiography. JAMA 2007; 298 (03) 317-323
    CrossrefPubMedGoogle Scholar
  • 15 Ginsberg JS, Hirsh J, Rainbow AJ, Coates G. Risks to the fetus of radiologic procedures used in the diagnosis of maternal venous thromboembolic disease. Thromb Haemost 1989; 61 (02) 189-196
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Kanal E, Barkovich AJ, Bell C. , et al; ACR Blue Ribbon Panel on MR Safety. ACR guidance document for safe MR practices: 2007. AJR Am J Roentgenol 2007; 188 (06) 1447-1474
    CrossrefPubMedGoogle Scholar
  • 17 Romualdi E, Dentali F, Rancan E. , et al. Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta-analysis of the literature. J Thromb Haemost 2013; 11 (02) 270-281
    CrossrefPubMedGoogle Scholar
  • 18 Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. Recommendations for prophylaxis of pregnancy-related venous thromboembolism in carriers of inherited thrombophilia. Comment on the 2012 ACCP guidelines: a rebuttal. J Thromb Haemost 2013; 11 (09) 1782-1784
    CrossrefPubMedGoogle Scholar
  • 19 Astedt B. Thrombotic and hemostatic problems in pregnancy and labor and their significance for the fetus and newborn infant [in German]. Padiatr Padol 1990; 25 (01) 43-53
    PubMedGoogle Scholar
  • 20 Bates SM, Ginsberg JS. Anticoagulants in pregnancy: fetal effects. Baillieres Clin Obstet Gynaecol 1997; 11 (03) 479-488
    CrossrefPubMedGoogle Scholar
  • 21 Pauli RM, Hall JG. Warfarin embryopathy. Lancet 1979; 2 (8134): 144
    PubMedGoogle Scholar
  • 22 Mehndiratta S, Suneja A, Gupta B, Bhatt S. Fetotoxicity of warfarin anticoagulation. Arch Gynecol Obstet 2010; 282 (03) 335-337
    CrossrefPubMedGoogle Scholar
  • 23 Bapat P, Kedar R, Lubetsky A. , et al. Transfer of dabigatran and dabigatran etexilate mesylate across the dually perfused human placenta. Obstet Gynecol 2014; 123 (06) 1256-1261
    CrossrefPubMedGoogle Scholar
  • 24 Bapat P, Pinto LS, Lubetsky A, Berger H, Koren G. Rivaroxaban transfer across the dually perfused isolated human placental cotyledon. Am J Obstet Gynecol 2015; 213 (05) 710.e1-710.e6
    CrossrefPubMedGoogle Scholar
  • 25 Bapat P, Pinto LS, Lubetsky A. , et al. Examining the transplacental passage of apixaban using the dually perfused human placenta. J Thromb Haemost 2016; 14 (07) 1436-1441
    CrossrefPubMedGoogle Scholar
  • 26 Bayer Pharma AG. Xarelto summary of product characteristics; 2016. Available at: http://www.medicines.org.uk/emc/medicine/25586/SPC
    PubMedGoogle Scholar
  • 27 Bristol-Myers Squibb-Pfizer. Eliquis summary of product characteristics; 2016. Available at: http://www.medicines.org.uk/emc/medicine/24988
    PubMedGoogle Scholar
  • 28 Boehringer-Ingelheim. Pradaxa summary of product characteristics; 2016. Available at: http://www.medicines.org.uk/EMC/medicine/24839/SPC/Pradaxa+150
    PubMedGoogle Scholar
  • 29 Beyer-Westendorf J, Michalski F, Tittl L. , et al. Pregnancy outcome in patients exposed to direct oral anticoagulants - and the challenge of event reporting. Thromb Haemost 2016; 116 (04) 651-658
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Cohen H, Arachchillage DR, Beyer-Westendorf J, Middeldorp S, Kadir RA. Direct oral anticoagulants and women. Semin Thromb Hemost 2016; 42 (07) 789-797
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007; 5 (03) 632-634
    CrossrefPubMedGoogle Scholar
  • 32 Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood 2013; 122 (10) 1712-1723
    CrossrefPubMedGoogle Scholar
  • 33 Prandoni P, Lensing AW, Piccioli A. , et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100 (10) 3484-3488
    CrossrefPubMedGoogle Scholar
  • 34 Lyman GH, Eckert L, Wang Y, Wang H, Cohen A. Venous thromboembolism risk in patients with cancer receiving chemotherapy: a real-world analysis. Oncologist 2013; 18 (12) 1321-1329
    CrossrefPubMedGoogle Scholar
  • 35 Cronin-Fenton DP, Søndergaard F, Pedersen LA. , et al. Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997-2006. Br J Cancer 2010; 103 (07) 947-953
    CrossrefPubMedGoogle Scholar
  • 36 Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006; 166 (04) 458-464
    CrossrefPubMedGoogle Scholar
  • 37 Louzada ML, Majeed H, Dao V, Wells PS. Risk of recurrent venous thromboembolism according to malignancy characteristics in patients with cancer-associated thrombosis: a systematic review of observational and intervention studies. Blood Coagul Fibrinolysis 2011; 22 (02) 86-91
    CrossrefPubMedGoogle Scholar
  • 38 Douma RA, van Sluis GL, Kamphuisen PW. , et al. Clinical decision rule and D-dimer have lower clinical utility to exclude pulmonary embolism in cancer patients. Explanations and potential ameliorations. Thromb Haemost 2010; 104 (04) 831-836
    Article in Thieme ConnectPubMedGoogle Scholar
  • 39 Wilts IT, Le Gal G, Den Exter PL. , et al. Performance of the age-adjusted cut-off for D-dimer in patients with cancer and suspected pulmonary embolism. Thromb Res 2017; 152: 49-51
    CrossrefPubMedGoogle Scholar
  • 40 Heit JA. Predicting the risk of venous thromboembolism recurrence. Am J Hematol 2012; 87 (Suppl. 01) S63-S67
    CrossrefPubMedGoogle Scholar
  • 41 Heit JA, Lahr BD, Petterson TM, Bailey KR, Ashrani AA, Melton III LJ. Heparin and warfarin anticoagulation intensity as predictors of recurrence after deep vein thrombosis or pulmonary embolism: a population-based cohort study. Blood 2011; 118 (18) 4992-4999
    CrossrefPubMedGoogle Scholar
  • 42 Gussoni G, Frasson S, La Regina M, Di Micco P, Monreal M. ; RIETE Investigators. Three-month mortality rate and clinical predictors in patients with venous thromboembolism and cancer. Findings from the RIETE registry. Thromb Res 2013; 131 (01) 24-30
    CrossrefPubMedGoogle Scholar
  • 43 Trujillo-Santos J, Nieto JA, Tiberio G. , et al; RIETE Registry. Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008; 100 (03) 435-439
    Article in Thieme ConnectPubMedGoogle Scholar
  • 44 Aujesky D, Obrosky DS, Stone RA. , et al. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med 2005; 172 (08) 1041-1046
    CrossrefPubMedGoogle Scholar
  • 45 Jiménez D, Aujesky D, Moores L. , et al; RIETE Investigators. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med 2010; 170 (15) 1383-1389
    CrossrefPubMedGoogle Scholar
  • 46 Carrier M, Righini M, Wells PS. , et al. Subsegmental pulmonary embolism diagnosed by computed tomography: incidence and clinical implications. A systematic review and meta-analysis of the management outcome studies. J Thromb Haemost 2010; 8 (08) 1716-1722
    CrossrefPubMedGoogle Scholar
  • 47 den Exter PL, Hooijer J, Dekkers OM, Huisman MV. Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: a comparison with symptomatic patients. J Clin Oncol 2011; 29 (17) 2405-2409
    CrossrefPubMedGoogle Scholar
  • 48 Cronin CG, Lohan DG, Keane M, Roche C, Murphy JM. Prevalence and significance of asymptomatic venous thromboembolic disease found on oncologic staging CT. AJR Am J Roentgenol 2007; 189 (01) 162-170
    CrossrefPubMedGoogle Scholar
  • 49 Douma RA, Kok MG, Verberne LM, Kamphuisen PW, Büller HR. Incidental venous thromboembolism in cancer patients: prevalence and consequence. Thromb Res 2010; 125 (06) e306-e309
    CrossrefPubMedGoogle Scholar
  • 50 Di Nisio M, Ferrante N, De Tursi M. , et al. Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Thromb Haemost 2010; 104 (05) 1049-1054
    Article in Thieme ConnectPubMedGoogle Scholar
  • 51 Browne AM, Cronin CG, English C, NiMhuircheartaigh J, Murphy JM, Bruzzi JF. Unsuspected pulmonary emboli in oncology patients undergoing routine computed tomography imaging. J Thorac Oncol 2010; 5 (06) 798-803
    CrossrefPubMedGoogle Scholar
  • 52 Dentali F, Ageno W, Giorgi Pierfranceschi M. , et al. Prognostic relevance of an asymptomatic venous thromboembolism in patients with cancer. J Thromb Haemost 2011; 9 (05) 1081-1083
    CrossrefPubMedGoogle Scholar
  • 53 Callejas MF, Errázuriz JI, Castillo F. , et al. Incidental venous thromboembolism detected by PET-CT in patients with cancer: prevalence and impact on survival rate. Thromb Res 2014; 133 (05) 750-755
    CrossrefPubMedGoogle Scholar
  • 54 Lyman GH, Khorana AA, Kuderer NM. , et al; American Society of Clinical Oncology Clinical Practice. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013; 31 (17) 2189-2204
    CrossrefPubMedGoogle Scholar
  • 55 Lee AY, Levine MN, Baker RI. , et al; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349 (02) 146-153
    CrossrefPubMedGoogle Scholar
  • 56 Lee AY, Bauersachs R, Janas MS. , et al; CATCH Investigators. CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. BMC Cancer 2013; 13: 284
    CrossrefPubMedGoogle Scholar
  • 57 Posch F, Königsbrügge O, Zielinski C, Pabinger I, Ay C. Treatment of venous thromboembolism in patients with cancer: a network meta-analysis comparing efficacy and safety of anticoagulants. Thromb Res 2015; 136 (03) 582-589
    CrossrefPubMedGoogle Scholar
  • 58 Bott-Kitslaar DM, Saadiq RA, McBane RD. , et al. Efficacy and safety of rivaroxaban in patients with venous thromboembolism and active malignancy: a single-center registry. Am J Med 2016; 129 (06) 615-619
    CrossrefPubMedGoogle Scholar
  • 59 Mahé I, Chidiac J, Bertoletti L. , et al; RIETE Investigators. The clinical course of venous thromboembolism may differ according to cancer site. Am J Med 2017; 130 (03) 337-347
    CrossrefPubMedGoogle Scholar
  • 60 Mantha S, Laube E, Miao Y. , et al. Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study. J Thromb Thrombolysis 2017; 43 (02) 166-171
    CrossrefPubMedGoogle Scholar
  • 61 Raskob GE, van Es N, Verhamme P. , et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018; 378: 615-624
    CrossrefPubMedGoogle Scholar
  • 62 Young A, Marshall A, Thirlwall J. , et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism: results of the Select-D™ pilot trial. Annual Meeting of the American Society of Hematology; 2017; oral abstract no. 625
    PubMedGoogle Scholar
  • 63 Heidbuchel H, Verhamme P, Alings M. , et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015; 17 (10) 1467-1507
    CrossrefPubMedGoogle Scholar
  • 64 Lutz J, Menke J, Sollinger D, Schinzel H, Thürmel K. Haemostasis in chronic kidney disease. Nephrol Dial Transplant 2014; 29 (01) 29-40
    CrossrefPubMedGoogle Scholar
  • 65 Monreal M, Falgá C, Valle R. , et al; RIETE Investigators. Venous thromboembolism in patients with renal insufficiency: findings from the RIETE Registry. Am J Med 2006; 119 (12) 1073-1079
    CrossrefPubMedGoogle Scholar
  • 66 Bauersachs R, Berkowitz SD, Brenner B. , et al; EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363 (26) 2499-2510
    CrossrefPubMedGoogle Scholar
  • 67 Büller HR, Prins MH, Lensin AW. , et al; EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366 (14) 1287-1297
    CrossrefPubMedGoogle Scholar
  • 68 Agnelli G, Buller HR, Cohen A. , et al; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369 (09) 799-808
    CrossrefPubMedGoogle Scholar
  • 69 Büller HR, Décousus H, Grosso MA. , et al; Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369 (15) 1406-1415
    CrossrefPubMedGoogle Scholar
  • 70 Schulman S, Kakkar AK, Goldhaber SZ. , et al; RE-COVER II Trial Investigators. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014; 129 (07) 764-772
    CrossrefPubMedGoogle Scholar
  • 71 Schulman S, Kearon C, Kakkar AK. , et al; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361 (24) 2342-2352
    CrossrefPubMedGoogle Scholar
  • 72 Chan KE, Lazarus JM, Thadhani R, Hakim RM. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 2009; 20 (10) 2223-2233
    CrossrefPubMedGoogle Scholar
  • 73 Hijazi Z, Oldgren J, Lindbäck J. , et al; ARISTOTLE and RE-LY Investigators. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet 2016; 387 (10035): 2302-2311
    CrossrefPubMedGoogle Scholar
  • 74 El-Abbadi M, Giachelli CM. Mechanisms of vascular calcification. Adv Chronic Kidney Dis 2007; 14 (01) 54-66
    CrossrefPubMedGoogle Scholar
  • 75 Brodsky SV, Nadasdy T, Rovin BH. , et al. Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate. Kidney Int 2011; 80 (02) 181-189
    CrossrefPubMedGoogle Scholar
  • 76 Kubitza D, Becka M, Mueck W. , et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol 2010; 70 (05) 703-712
    CrossrefPubMedGoogle Scholar
  • 77 Chang M, Yu Z, Shenker A. , et al. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban. J Clin Pharmacol 2016; 56 (05) 637-645
    CrossrefPubMedGoogle Scholar
  • 78 Stangier J, Rathgen K, Stähle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010; 49 (04) 259-268
    CrossrefPubMedGoogle Scholar
  • 79 Prins MH, Lensing AW, Bauersachs R. , et al; EINSTEIN Investigators. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 2013; 11 (01) 21
    CrossrefPubMedGoogle Scholar
  • 80 Bauersachs RM, Lensing AW, Prins MH. , et al. Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment. Thromb J 2014; 12: 25
    CrossrefPubMedGoogle Scholar
  • 81 Pathak R, Pandit A, Karmacharya P. , et al. Meta-analysis on risk of bleeding with apixaban in patients with renal impairment. Am J Cardiol 2015; 115 (03) 323-327
    CrossrefPubMedGoogle Scholar
  • 82 Verhamme P, Wells PS, Segers A. , et al. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thromb Haemost 2016; 116 (04) 747-753
    Article in Thieme ConnectPubMedGoogle Scholar
  • 83 De Vriese AS, Caluwé R, Bailleul E. , et al. Dose-finding study of rivaroxaban in hemodialysis patients. Am J Kidney Dis 2015; 66 (01) 91-98
    CrossrefPubMedGoogle Scholar
  • 84 Wang X, Tirucherai G, Marbury TC. , et al. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol 2016; 56 (05) 628-636
    CrossrefPubMedGoogle Scholar
  • 85 Goldhaber SZ, Schellong S, Kakkar A. , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thromb Haemost 2016; 116 (04) 714-721
    Article in Thieme ConnectPubMedGoogle Scholar
  • 86 Henriksson P, Westerlund E, Wallén H, Brandt L, Hovatta O, Ekbom A. Incidence of pulmonary and venous thromboembolism in pregnancies after in vitro fertilisation: cross sectional study. BMJ 2013; Jan 15; 346 (04) e8632 . doi: 10.1136/bmj.e8632
    CrossrefPubMedGoogle Scholar